Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
Status:
Withdrawn
Trial end date:
2021-10-14
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety and tolerability of SLN124 for
the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic
syndrome.